u 92032 has been researched along with flunarizine in 2 studies
| Studies (u 92032) | Trials (u 92032) | Recent Studies (post-2010) (u 92032) | Studies (flunarizine) | Trials (flunarizine) | Recent Studies (post-2010) (flunarizine) |
|---|---|---|---|---|---|
| 9 | 0 | 1 | 1,269 | 189 | 153 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Annoura, H; Imajo, S; Miyajima, A; Nakanishi, K; Takemoto, N; Tamura, S; Tamura-Horikawa, Y; Toba, T | 1 |
| Im, WB; Ito, C; Kunihara, M; Liou, SY; Takagi, H; Takahashi, M; Tsuzuki, K | 1 |
2 other study(ies) available for u 92032 and flunarizine
| Article | Year |
|---|---|
Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a dual Na(+) and Ca(2+) channel blocker with antioxidant activity.
Topics: Acoustic Stimulation; Aniline Compounds; Animals; Anticonvulsants; Antioxidants; Calcium Channel Blockers; Cerebral Cortex; In Vitro Techniques; Lipid Peroxidation; Mice; Mice, Inbred DBA; Models, Molecular; Molecular Conformation; Neuroprotective Agents; Piperazines; Rats; Seizures; Sodium Channel Blockers | 2000 |
U-92032, a T-type Ca2+ channel blocker and antioxidant, reduces neuronal ischemic injuries.
Topics: Animals; Antioxidants; Brain Ischemia; Calcium Channel Blockers; Flunarizine; Gerbillinae; Hippocampus; Lipid Peroxidation; Long-Term Potentiation; Malondialdehyde; Mice; Neuroblastoma; Neurons; Piperazines; Rats; Tropolone; Tumor Cells, Cultured | 1994 |